CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
Feature|Articles|May 5, 2026
Psychedelic Therapy EO Is a Major Step for Mental Health, but Access Barriers Remain, Experts Say
Author(s)Giuliana Grossi
Fact checked by: Christina Mattina
New executive order fast-tracks psychedelic therapy research for veterans, but VA rollout, DEA rescheduling, and insurance hurdles still loom.
Advertisement
Advertisement
For decades, psychedelic medicine has occupied a complex and often contentious space between restrictive federal scheduling and emerging clinical research. However, a recent
Related to this article
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
Advertisement
Advertisement